β-Agonists and asthma: too much of a good thing?
In an unusual paradox, asthmatics who are chronically treated with bronchodilating β-agonists sometimes experience a worsening of their condition. A new study describes one possible mechanism and reveals a potential new therapeutic target in the treatment of asthma.
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2003
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC171402/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/12925688/ https://ncbi.nlm.nih.govhttps://doi.org/10.1172/JCI19642 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|